valsartan has been researched along with Cardiac Output, Low in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (7.14) | 18.2507 |
| 2000's | 10 (71.43) | 29.6817 |
| 2010's | 3 (21.43) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ambrosy, AP; Braunwald, E; DeVore, AD; Duffy, CI; Hernandez, AF; McCague, K; Morrow, DA; Rocha, RA; Velazquez, EJ | 1 |
| Bösch, C; Dobner, S; Hunziker, L; Martinelli, M; Rhyner, D; Schnegg, B; Suter, T; Wieser, M; Wigger, O | 1 |
| Ambrosy, AP; Braunwald, E; DeVore, AD; Duffy, CI; McCague, K; Morrow, DA; Rocha, R; Velazquez, EJ | 1 |
| Krum, H; Martin, J | 1 |
| Glazer, R; Gurrieri, P; McLeod, J; Prasad, PP; Yeh, CM | 1 |
| Anand, IS; Chiang, YT; Cohn, JN; Glazer, R; Latini, R; Masson, S | 1 |
| Califf, RM; Diaz, R; Ertl, G; Køber, L; Leimberger, JD; Maggioni, AP; Mareev, V; McMurray, JJ; Opolski, G; Pfeffer, MA; Rouleau, JL; Solomon, SD; Swedberg, K; Van de Werf, F; Velazquez, EJ; Zannad, F; Zelenkofske, S | 1 |
| Amerena, J; Balazovjech, I; Brunner, HR; Cassel, G; Herczeg, B; Hua, TA; Julius, S; Kjeldsen, SE; Koylan, N; Laragh, J; Magometschnigg, D; Majahalme, S; Martinez, F; McInnes, GT; Oigman, W; Schork, MA; Seabra Gomes, R; Weber, MA; Zanchetti, A; Zhu, JR | 1 |
| Baklanova, NA; Belenkov, IuN; Mareev, VIu; Masenko, VP; Nasonova, SN; Orlova, IaA; Skvortsov, AA; Sychev, AV | 1 |
| Liu, PP; Maggioni, A; Velazquez, EJ | 1 |
| Jugdutt, BI | 1 |
| Goldstein, S; Levine, TB; Mishima, T; Sabbah, HN; Sharov, VG; Shimoyama, H; Tanimura, M | 1 |
| Houghton, AR | 1 |
4 review(s) available for valsartan and Cardiac Output, Low
| Article | Year |
|---|---|
[Pharmacological therapy of heart failure with reduced ejection fraction].
Topics: Adrenergic beta-Antagonists; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Biphenyl Compounds; Cardiac Output, Low; Combined Modality Therapy; Diuretics; Drug Combinations; Drug Therapy, Combination; Heart Failure; Humans; Ivabradine; Life Style; Mineralocorticoid Receptor Antagonists; Stroke Volume; Tetrazoles; Valsartan | 2018 |
Role of valsartan and other angiotensin receptor blocking agents in the management of cardiovascular disease.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Cardiac Output, Low; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus; Humans; Hypertension; Hypertrophy, Left Ventricular; Kidney Failure, Chronic; Myocardial Infarction; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2002 |
Valsartan in the treatment of heart attack survivors.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Cardiac Output, Low; Humans; Myocardial Infarction; Randomized Controlled Trials as Topic; Renin-Angiotensin System; Research Design; Secondary Prevention; Tetrazoles; Treatment Outcome; Valine; Valsartan; Ventricular Dysfunction, Left; Ventricular Remodeling | 2006 |
Angiotensin II receptor antagonists in chronic heart failure: where do they fit?
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cardiac Output, Low; Chronic Disease; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2002 |
7 trial(s) available for valsartan and Cardiac Output, Low
| Article | Year |
|---|---|
Rationale and design of the comParIson Of sacubitril/valsartaN versus Enalapril on Effect on nt-pRo-bnp in patients stabilized from an acute Heart Failure episode (PIONEER-HF) trial.
Topics: Administration, Oral; Aged; Aminobutyrates; Biphenyl Compounds; Cardiac Output, Low; Cause of Death; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Drug Delivery Systems; Enalapril; Female; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Patient Safety; Peptide Fragments; Prognosis; Prospective Studies; Risk Assessment; Severity of Illness Index; Survival Rate; Tetrazoles; Treatment Outcome; Valsartan | 2018 |
Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure.
Topics: Acute Disease; Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Cardiac Output, Low; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Enalapril; Female; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Neprilysin; Peptide Fragments; Stroke Volume; Tetrazoles; Valsartan | 2019 |
Pharmacokinetics of multiple doses of valsartan in patients with heart failure.
Topics: Angiotensin Receptor Antagonists; Area Under Curve; Cardiac Output, Low; Dose-Response Relationship, Drug; Female; Half-Life; Humans; Male; Metabolic Clearance Rate; Middle Aged; Tetrazoles; Valine; Valsartan | 2002 |
Sustained reduction of aldosterone in response to the angiotensin receptor blocker valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial.
Topics: Aldosterone; Angiotensin Receptor Antagonists; Cardiac Output, Low; Chronic Disease; Double-Blind Method; Follow-Up Studies; Humans; Tetrazoles; Valine; Valsartan | 2003 |
Previously known and newly diagnosed atrial fibrillation: a major risk indicator after a myocardial infarction complicated by heart failure or left ventricular dysfunction.
Topics: Acute Disease; Aged; Angiotensin II Type 1 Receptor Blockers; Atrial Fibrillation; Captopril; Cardiac Output, Low; Female; Humans; Male; Middle Aged; Myocardial Infarction; Outcome Assessment, Health Care; Prognosis; Proportional Hazards Models; Risk Assessment; Risk Factors; Survival Analysis; Tetrazoles; Time Factors; Valine; Valsartan; Ventricular Dysfunction, Left | 2006 |
The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial: outcomes in patients receiving monotherapy.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Cardiac Output, Low; Diabetes Mellitus; Double-Blind Method; Drug Administration Schedule; Female; Humans; Hypertension; Incidence; Male; Middle Aged; Risk; Tetrazoles; Valine; Valsartan | 2006 |
[Effects of long term therapy with angiotensin converting enzyme inhibitor quinapril, antagonist of receptors to angiotensin II valsartan, and combination of quinapril and valsartan in patients with moderate chronic heart failure. Main results of the SADK
Topics: Adult; Aged; Aldosterone; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Cardiac Output, Low; Chronic Disease; Drug Therapy, Combination; Exercise Tolerance; Female; Heart Rate; Humans; Male; Middle Aged; Norepinephrine; Quinapril; Tetrahydroisoquinolines; Tetrazoles; Treatment Outcome; Valine; Valsartan; Ventricular Remodeling | 2006 |
3 other study(ies) available for valsartan and Cardiac Output, Low
| Article | Year |
|---|---|
These drugs are an ACE in the hole. Angiotensin receptor blockers prove okay when an ACE inhibitor causes problems.
Topics: Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Biphenyl Compounds; Captopril; Cardiac Output, Low; Cough; Humans; Receptor, Angiotensin, Type 1; Tetrazoles; Valine; Valsartan | 2004 |
Use of valsartan in post-myocardial infarction and heart failure patients.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Cardiac Output, Low; Humans; Myocardial Infarction; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left | 2006 |
Effects of AT1-receptor blockade on progression of left ventricular dysfunction in dogs with heart failure.
Topics: Angiotensin Receptor Antagonists; Animals; Cardiac Output, Low; Disease Progression; Dogs; Dose-Response Relationship, Drug; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left; Ventricular Remodeling | 1999 |